维普期刊资源整合服务平台（V6.5）

289篇 您的检索式：作者名="GOMIS R"

选中清除导出查看参考文献查看引证文献引用追踪共15页首页上一页第1页下一页末页 /15 跳转

	题名	作者	年代	出处	被引量
1	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance; The STOP - NIDDM trial 显示文摘	Chiasson JL Josse RG Gomis R	2003	JAMA2003，290，4：	1
2	Acarbose treatment and the risk of cardiovascular disease and hypertension in impaired glucose tolerance:the STOP-NIDDM trial显示文摘	Chiaeeon J L Josse R G Gomis R	2003	JAMA2003，290，4：	1
3	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial显示文摘	Chiasson JL Josse RC Gomis R	2003	J Ame Med Associat2003，290，4：	1
4	The logic of TGF beta signaling显示文摘	MassaguéJ Gomis R R	2006	FEBS Lett2006，580，12：	1
5	The effect of prandial glucose regulation with repaglinide on effect satisfaction, wellbeing and health status in patients with pharmacotherapy - nave Type 2 diabetes: A placebo - controlled, multicenter stuty 显示文摘	Bech P Moses R Gomis R	2003	Qual life Res2003，12，4：	1
6	Acarbose for prevention of type 2diabetes mellitus:the STOP-NIDDM randomised trial显示文摘	Chiasson JL Josse RG Gomis R	2002	Lancet2002，359，9323：	1
7	Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial显示文摘	Chiasson JL Josse RG Gomis R	2002	Lancet2002，359，9323：	1
8	Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomisedtrial显示文摘	Chiasson JL Josse RG Gomis R	2002	Lancet2002，359，9323：	1
9	Twelve and 52 week efficacy of the dipcptidyl peptidase Ⅳ inhibitor LAF237 in metformin-treated patients with type 2 diabetes 显示文摘	Ahren B Gomis R Standl E	2004	Diabetes Care2004，27，12：	1
10	Acarbose treatment and the risk ofcardiovascular disease and hypertension in patients with impaired glucosetolerance显示文摘	Chiasson JL Josse RG Gomis R	2003	JAMA2003，290，4：	1
11	The logic of TGFβ signaling显示文摘	Massague J Gomis R R	2006	FEBS Lett2006，580，12：	1
12	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial显示文摘	Chiasson JL Josse RG Gomis R	2003	JAMA2003，290，：	1
13	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial显示文摘	Chiasson JL Josse RG Gomis R	2003	JAMA2003，290，4：	1
14	Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes显示文摘	Ahrén B Gomis R Standl E	2004	Diabetes Care2004，27，12：	1
15	Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized,double-blind,placebo-controlled study显示文摘	Gomis R Espadero RM Jones R	2011	Diabetes Obes Metab2011，13，7：	1
16	Cerebrovascular in- flammation following subarachnoid hemorrhage 显示文摘	Sercombe R Dinh YR Gomis P	2002	Pharmacol2002，88，3：	1
17	Acarbose for preven- tion of type 2 diabetes mellitus: the STOP-NIDDM randomised trial显示文摘	Chiasson J L Josse R G Gomis R	2002	The Lancet2002，359，9323：	1
18	Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes 显示文摘	Gomis R Frandsen KB	2001	Diabetes Care2001，24，：	1
19	Acarbose treatment and the risk of cardiovascular disease and hypertension in pa- tients with impaired glucose tolerance-the STOP-NIDDM trial 显示文摘	Chiasson J L Josse R G Gomis R	2003	JAMA-Journal of the American Medical Association2003，290，4：	1
20	Isobaric vapour-liquid and vapour-liquid-liquid equilibrium data for the sys- tem water+ ethanol+ cyclohexane显示文摘	GOMIS V FONT A PEDRAZA R	2005	Fluid Phase Equilib2005，235，4：	1

返回顶部每页显示：

共15页首页上一页第1页下一页末页 /15 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示